# Angitia Biopharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/angitia-biopharmaceuticals

- Industry: Biotechnology
- Headquarters: Westlake Village, US
- Website: www.angitiabio.com/
- Total disclosed funding: $406M
- Latest round: Series D (Feb 5, 2026)
- Investors on record: 26

## About

Founded in 2018 and based in California, US, Angitia Biopharmaceuticals Limited operates as a biotechnology company that develops therapies for musculoskeletal diseases. Established in 2018 and based in Guangzhou, China, Angitia Biopharmaceuticals Guangzhou Limited is a biotechnology company that focuses on the research and development of therapeutics for musculoskeletal diseases. The founder and CEO Prof. Huazhu Ke held the positions of Vice President and Head of Bone Therapeutics Areas at UCB Pharma, Scientific Executive Director of Bone and Kidney Research at Amgen Inc., and has more than 30 years of experience in R&D management and industrialization of bone disease drugs. In 2019, a bone and joint new drug development platform was released. In February 2026, Angitia Biopharmaceuticals Limited raised USD 130 million in series D funding co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners, with participation from Ascenta Capital, Blackrock, BVF Partners, Logos Capital, RA Capital Management, Wellington Management, Bain Capital Life Sciences, Elikon Venture, Janus Henderson Investors, 3H Health Investment Management (Hong Kong) Limited, Hillhouse Investment, Legend Capital, Morningside Private Investors, OrbiMed Advisors, TF Capital, and Yonghua Capital. 
The company focuses on the research and development of new drugs for bone, joint, and muscle diseases including spinal degenerative diseases, osteoporosis, osteogenesis imperfecta, tumor bone metastasis, etc. The pipeline of drugs under development includes AGA111 and AGA2118, etc.
The company will use the February 2026 funding raised to support the clinical development of its therapeutic pipeline.

## Funding rounds

- Series D, Feb 5, 2026, $130M — Frazier Healthcare Partners, OrbiMed Advisors, Bain Capital, Legend Capital, Wellington Management, BlackRock, Hillhouse Investment, Yonghua Capital, BVF Partners, RA Capital Management, Morningside Private Investors, TF Capital, Janus Henderson Investors, 3H Health Investment, Venrock Healthcare Capital Partners, Logos Capital, Elikon Venture, Ascenta Capital
- Series C, Dec 11, 2024, $120M — OrbiMed Advisors, Bain Capital, Legend Capital, Yonghua Capital, Janus Henderson Investors, 3H Health Investment, Elikon Venture
- Series B, Jan 1, 2024, $40M — Yuekai Capital
- Series B, Oct 19, 2023, $46M — OrbiMed Advisors, Legend Capital, 5Y Capital, Oriza Holdings, Yonghua Capital, 3H Health Investment, Elikon Venture
- Series B, Oct 31, 2021, $70M — OrbiMed Advisors, Legend Capital, 5Y Capital, Oriza Holdings, CMB International Asset Management, 3H Health Investment, Firstlight Capital, GL Ventures, Guangzhou Junshi Asset Management, Elikon Venture, Honghai Ventures
- Series A, Aug 19, 2020 — OrbiMed Advisors, Oriza Holdings, Yonghua Capital, TF Capital, GL Ventures, Guangzhou Junshi Asset Management
- Angel, Mar 21, 2019 — Yonghua Capital, TF Capital, Guangzhou Junshi Asset Management

## Investors

- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Angel, Series A, Series B, Series C, Series D
- TF Capital — Angel, Series A, Series D
- Guangzhou Junshi Asset Management — Angel, Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series C, Series D
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A, Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A, Series B
- Legend Capital — Series B, Series C, Series D
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series B
- 3H Health Investment (https://capitalatlas.ai/funds/3h-health-investment) — Series B, Series C, Series D
- Firstlight Capital — Series B
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Series B, Series C, Series D
- Honghai Ventures — Series B
- Yuekai Capital (https://capitalatlas.ai/funds/yuekai-capital) — Series B
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series C, Series D
- Janus Henderson Investors — Series C, Series D
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series D
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series D
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series D
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series D
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series D
- Morningside Private Investors (https://capitalatlas.ai/funds/morningside-private-investors) — Series D
- Venrock Healthcare Capital Partners (https://capitalatlas.ai/funds/venrock-healthcare-capital-partners) — Series D
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series D
- Ascenta Capital (https://capitalatlas.ai/funds/ascenta-capital) — Series D